YC-6在患有大半球心脏病的患者中的安全性和可行性:一项随机临床试验
Huiqing Hou1,2, Baoyu Feng2, Dawei Zang1,2
1Department of Rehabilitation Medicine, Beijing Tiantan Hospital Capital Medical University Beijing China.
Journal of the American Heart Association
|October 28, 2025
概括
在患有大半球梗塞的患者中,YC-6 (5α-androst-3β,5,6β-triol注射) 显示出与安慰剂相似的安全性和有效性. 在第二阶段试验中需要进一步调查.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 恶性脑显著影响大半球心脏病发作的结果.
- 新型神经保护剂对于改善患者预后至关重要.
- YC-6 (5α-androst-3β,5,6β-triol用于注射) 是一个潜在的治疗候选者.
研究的目的:
- 评估YC-6的安全性和初步可行性,用于患有大半球梗塞的患者.
- 为了评估与安慰剂相比YC-6的疗效.
主要方法:
- 一个前性的,随机的,双盲的,安慰剂控制的,概念验证试验.
- 中脑动脉梗塞的患者每天两次服用300毫克YC-6或安慰剂,持续10天.
- 主要结局包括严重的不良事件,全因死亡和90天后修改的兰金度量得分.
主要成果:
- 严重不良事件和全因死亡率在YC-6和安慰剂组之间是可比的.
- 在修改后的兰金级分数分布中没有观察到统计学意义上的差异.
- YC-6在数值上减少了水体积和中线移动,表明了潜在的治疗益处.
结论:
- 对于患有大半球梗塞的患者来说,YC-6似乎是安全的和可行的.
- 这些初步发现支持在第二阶段临床试验中对YC-6进行进一步调查.
- YC-6显示出作为中风治疗的神经保护剂的潜力.
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic Studies
207
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
207
01:30Acute Coronary Syndrome I: Introduction
785
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
785